Inobrodib
- Generic Name
- Inobrodib
- Drug Type
- Small Molecule
- CAS Number
- 2222941-37-7
- Unique Ingredient Identifier
- BW5QA5GEW7
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1
Recruiting
- Conditions
- Non Hodgkin LymphomaHaematological MalignancyAcute Myeloid LeukemiaHigher-risk Myelodysplastic SyndromeMultiple MyelomaPeripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT04068597
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇺🇸The Center for Cancer and Blood Disorders (CCBD), Bethesda, Maryland, United States
Study to Evaluate CCS1477 in Advanced Tumours
Phase 1
Active, not recruiting
- Conditions
- Metastatic Castration-Resistant Prostate CancerNon-small Cell Lung CancerMetastatic Breast CancerAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT03568656
- Locations
- 🇫🇷
Institute Gustave Roussy, Villejuif, France
🇳🇱Netherlands Cancer Institute (NKI), Amsterdam, Netherlands
🇪🇸Hospital Vall d'Hebron, VHIO, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath